Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Share:
Related CERN
Benzinga's Top Upgrades, Downgrades For August 10, 2017
The Market In 5 Minutes
Related ABCO
Wall Street's M&A Chatter From July 20: Scripps Network, Rent-A-Center, Aircastle, Advisory Board
Bernstein On Advisory Board Health Care Services Unit Purchase By UnitedHealth
ADVISORY BOARD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ... (GuruFocus)

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Aug 2017Morgan StanleyUpgradesUnderweightEqual-Weight
May 2017Hilliard LyonsDowngradesLong-Term BuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

View Comments and Join the Discussion!